Medical Therapy to Prevent or Slow Progression of Aortic Stenosis: Current Evidence and Future Directions.
暂无分享,去创建一个
D. Playford | G. Dwivedi | G. Strange | A. Ihdayhid | N. Lan | G. Hillis | T. Chong | William Courtney | Albert He | William A Courtney | W. Courtney | A. Ihdayhid
[1] D. Playford,et al. Counting the cost of premature mortality with progressively worse aortic stenosis in Australia: a clinical cohort study , 2022, The Lancet. Healthy longevity.
[2] D. Playford,et al. Increasing risk of mortality across the spectrum of aortic stenosis is independent of comorbidity & treatment: An international, parallel cohort study of 248,464 patients , 2022, PloS one.
[3] J. Lindholt,et al. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial , 2022, Circulation.
[4] C. Bauters,et al. Association of Mortality With Aortic Stenosis Severity in Outpatients: Results From the VALVENOR Study. , 2021, JAMA cardiology.
[5] B. Prendergast,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. , 2021, European heart journal.
[6] S. Stewart,et al. Incident aortic stenosis in 49 449 men and 42 229 women investigated with routine echocardiography , 2021, Heart.
[7] E. V. van Beek,et al. Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis , 2021, Circulation.
[8] M. Mack,et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.
[9] M. Mack,et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.
[10] J. Moon,et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis , 2020, Journal of the American College of Cardiology.
[11] G. Cho,et al. Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis , 2020, Heart.
[12] G. Hankey,et al. Colchicine in Patients with Chronic Coronary Disease. , 2020, The New England journal of medicine.
[13] G. Alishiri,et al. Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study , 2020, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.
[14] N. Weissman,et al. Left Ventricular Hypertrophy and Clinical Outcomes Over 5 Years After TAVR: An Analysis of the PARTNER Trials and Registries. , 2020, JACC. Cardiovascular interventions.
[15] N. Weissman,et al. Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries. , 2020, Journal of the American College of Cardiology.
[16] J. Hallas,et al. Association of aortic valve calcification and vitamin K antagonist treatment. , 2020, European heart journal cardiovascular Imaging.
[17] J. Moon,et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation , 2020, European heart journal.
[18] Lawrence A Leiter,et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. , 2020, The New England journal of medicine.
[19] A. Masri,et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis , 2020, European journal of heart failure.
[20] M. Dweck,et al. Pathophysiology of Aortic Stenosis and Future Perspectives for Medical Therapy. , 2020, Cardiology clinics.
[21] Deepak L. Bhatt,et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. , 2020, Journal of the American College of Cardiology.
[22] J. Tardif,et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. , 2020, The New England journal of medicine.
[23] J. Witztum,et al. Statin therapy increases lipoprotein(a) levels. , 2020, European heart journal.
[24] Christopher N. Foley,et al. Genetic Determinants of Lipids and Cardiovascular Disease Outcomes , 2019, Circulation. Genomic and precision medicine.
[25] R. Diaz,et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.
[26] G. Tell,et al. Association of Low-Density Lipoprotein Cholesterol With Risk of Aortic Valve Stenosis in Familial Hypercholesterolemia. , 2019, JAMA cardiology.
[27] S. Stewart,et al. Poor Long-term Survival in Patients with Moderate Aortic Stenosis. , 2019, Journal of the American College of Cardiology.
[28] M. Dweck,et al. Why and How to Measure Aortic Valve Calcification in Patients With Aortic Stenosis. , 2019, JACC. Cardiovascular imaging.
[29] M. Koschinsky,et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. , 2022, Journal of clinical lipidology.
[30] Michael A. Raddatz,et al. Celecoxib Is Associated With Dystrophic Calcification and Aortic Valve Stenosis , 2019, JACC. Basic to translational science.
[31] M. Dweck,et al. The Role of Imaging in Measuring Disease Progression and Assessing Novel Therapies in Aortic Stenosis , 2019, JACC. Cardiovascular imaging.
[32] A. Keech,et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial , 2019, Circulation.
[33] J. Carroll,et al. Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement , 2018, JAMA.
[34] P. Pibarot,et al. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial , 2018, JAMA cardiology.
[35] W. Kernan,et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetologia.
[36] Irl B Hirsch,et al. AACE/ACE Consensus Statement CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY , 2018 .
[37] P. Kadowitz,et al. The Nitric Oxide Pathway in Pulmonary Vascular Disease. , 2017, The American journal of cardiology.
[38] M. Leon,et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.
[39] S. Saito,et al. Renin–angiotensin system blockade therapy after transcatheter aortic valve implantation , 2017, Heart.
[40] J. Sörensen,et al. Metoprolol Reduces Hemodynamic and Metabolic Overload in Asymptomatic Aortic Valve Stenosis Patients: A Randomized Trial , 2017, Circulation. Cardiovascular imaging.
[41] G. Sullivan,et al. Valve Interstitial Cells: The Key to Understanding the Pathophysiology of Heart Valve Calcification , 2017, Journal of the American Heart Association.
[42] L. Schurgers,et al. Slower Progress of Aortic Valve Calcification With Vitamin K Supplementation: Results From a Prospective Interventional Proof-of-Concept Study. , 2017, Circulation.
[43] Ki-Up Lee,et al. Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells , 2017, Circulation.
[44] V. Salomaa,et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium , 2017, European heart journal.
[45] T. Tamura,et al. Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: the Takayama study. , 2017, The American journal of clinical nutrition.
[46] Y. Bossé,et al. Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study , 2017, European heart journal cardiovascular Imaging.
[47] Gonçalo R. Abecasis,et al. Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. , 2016, Journal of the American College of Cardiology.
[48] M. Leon,et al. Medical Treatment of Aortic Stenosis , 2016, Circulation.
[49] P. Libby,et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. , 2016, The New England journal of medicine.
[50] Ž. Reiner,et al. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. , 2016, Metabolism: clinical and experimental.
[51] C. R. Macedo,et al. Statins for aortic valve stenosis. , 2016, The Cochrane database of systematic reviews.
[52] B. Nordestgaard,et al. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis. , 2016, The Journal of clinical endocrinology and metabolism.
[53] J. Tardif,et al. Resting heart rate as a predictor of aortic valve stenosis progression. , 2016, International journal of cardiology.
[54] W. C. O'Neill,et al. Increased Peripheral Arterial Calcification in Patients Receiving Warfarin , 2016, Journal of the American Heart Association.
[55] M. Weyant,et al. Matrix Gla protein regulates calcification of the aortic valve. , 2015, The Journal of surgical research.
[56] G. Cioffi,et al. See Clinical Perspective See Editorial by Barasch and Reichek , 2022 .
[57] J. Zhan,et al. The protective effect of GLP-1 analogue in arterial calcification through attenuating osteoblastic differentiation of human VSMCs. , 2015, International journal of cardiology.
[58] B. Prendergast,et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial) , 2015, European heart journal cardiovascular Imaging.
[59] P. Okin,et al. Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study. , 2015, International journal of cardiology.
[60] Michael J Blaha,et al. Relation of resting heart rate to risk for all-cause mortality by gender after considering exercise capacity (the Henry Ford exercise testing project). , 2014, The American journal of cardiology.
[61] P. Pibarot,et al. Left Ventricular Remodeling in Aortic Stenosis , 2014 .
[62] L. Køber,et al. Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. , 2014, International journal of cardiology.
[63] Susan Cheng,et al. Long‐term Cardiovascular Risks Associated With an Elevated Heart Rate: The Framingham Heart Study , 2014, Journal of the American Heart Association.
[64] P. Barter,et al. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). , 2014, The American journal of cardiology.
[65] Y. Bossé,et al. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. , 2014, Journal of the American College of Cardiology.
[66] C. Hassager,et al. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study. , 2014, American heart journal.
[67] M. Sandhu,et al. Lipoprotein(a) levels, genotype and incident aortic stenosis: a prospective Mendelian randomization study and replication in a case-control cohort , 2013 .
[68] B. Nordestgaard,et al. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.
[69] S. Body,et al. Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease. , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[70] R. Bonow,et al. Current management of calcific aortic stenosis. , 2013, Circulation research.
[71] B. Lilly,et al. Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease. , 2013, Journal of molecular and cellular cardiology.
[72] P. Kovanen,et al. Modified Lipoprotein-Derived Lipid Particles Accumulate in Human Stenotic Aortic Valves , 2013, PloS one.
[73] R. Brooks,et al. Osteoprotegerin Inhibits Aortic Valve Calcification and Preserves Valve Function in Hypercholesterolemic Mice , 2013, PloS one.
[74] J. Uitto,et al. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. , 2013, Trends in molecular medicine.
[75] A. Luttun,et al. Increased Cardiac Myocyte PDE5 Levels in Human and Murine Pressure Overload Hypertrophy Contribute to Adverse LV Remodeling , 2013, PloS one.
[76] Joseph Chen,et al. Cadherin-11 Regulates Cell–Cell Tension Necessary for Calcific Nodule Formation by Valvular Myofibroblasts , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[77] R. Sacco,et al. Higher Ambulatory Blood Pressure Is Associated With Aortic Valve Calcification in the Elderly: A Population-Based Study , 2013, Hypertension.
[78] J. Peteiro,et al. Association of Left Ventricular Mass with All-Cause Mortality, Myocardial Infarction and Stroke , 2012, PloS one.
[79] Oakland J. Peters,et al. Predicting new indications for approved drugs using a proteochemometric method. , 2012, Journal of medicinal chemistry.
[80] J. Després,et al. Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. , 2012, Journal of the American College of Cardiology.
[81] E. Staal,et al. Hypertension in Aortic Stenosis: Implications for Left Ventricular Structure and Cardiovascular Events , 2012, Hypertension.
[82] B. Gage,et al. Effects of Phosphodiesterase Type 5 Inhibition on Systemic and Pulmonary Hemodynamics and Ventricular Function in Patients With Severe Symptomatic Aortic Stenosis , 2012, Circulation.
[83] J. J. Rivera,et al. The relationship between resting heart rate and incidence and progression of coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). , 2012, Atherosclerosis.
[84] J. Després,et al. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves , 2011, European journal of clinical investigation.
[85] K. J. Grande-Allen,et al. Calcific Aortic Valve Disease : Not Simply a Degenerative Process A Review and Agenda for Research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group , 2012 .
[86] C. Lang,et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. , 2011, Journal of the American College of Cardiology.
[87] B. Mulder,et al. Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS Trial). , 2011, The American journal of cardiology.
[88] Yuan Zhang,et al. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations , 2011, British journal of pharmacology.
[89] E. Aikawa,et al. Cardiovascular calcification: an inflammatory disease. , 2011, Circulation journal : official journal of the Japanese Circulation Society.
[90] K. Linhartová,et al. Bisphosphonates in Calcific Aortic Stenosis: Association with Slower Progression in Mild Disease – A Pilot Retrospective Study , 2010, Cardiology.
[91] R. Kronmal,et al. Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis). , 2010, Journal of the American College of Cardiology.
[92] J. Bauersachs,et al. Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. , 2010, Pharmacological research.
[93] F. Salvi,et al. Transthyretin-related amyloidoses and the heart: a clinical overview , 2010, Nature Reviews Cardiology.
[94] S. Siu,et al. Bicuspid aortic valve disease. , 2010, Journal of the American College of Cardiology.
[95] Erkki Vartiainen,et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. , 2010, American heart journal.
[96] R. Kronmal,et al. Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA). , 2010, The American journal of cardiology.
[97] K. Teo,et al. Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.
[98] Børge G Nordestgaard,et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.
[99] Eugenio Cervesato,et al. Hydroxymethylglutaryl coenzyme-a reductase inhibitors delay the progression of rheumatic aortic valve stenosis a long-term echocardiographic study. , 2009, Journal of the American College of Cardiology.
[100] Robert David,et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. , 2009, Cell stem cell.
[101] D. Grobbee,et al. High dietary menaquinone intake is associated with reduced coronary calcification. , 2009, Atherosclerosis.
[102] Georgios A. Dalkas,et al. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. , 2008, American journal of physiology. Heart and circulatory physiology.
[103] J. Chambers,et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.
[104] R. Brooks,et al. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. , 2008, Journal of the American College of Cardiology.
[105] B. Psaty,et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. , 2007, Journal of the American College of Cardiology.
[106] Jean-Claude Tardif,et al. Resting heart rate in cardiovascular disease. , 2007, Journal of the American College of Cardiology.
[107] J. Zamorano,et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. , 2007, Journal of the American College of Cardiology.
[108] K. Griendling,et al. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. , 2007, American journal of physiology. Cell physiology.
[109] R. Bansal,et al. Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. , 2006, The Annals of thoracic surgery.
[110] Damien Garcia,et al. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. , 2005, Journal of the American College of Cardiology.
[111] R. Prescott,et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.
[112] M. Budoff,et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. , 2005, Archives of internal medicine.
[113] D. Kass,et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.
[114] M. Mäyränpää,et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. , 2004, Journal of the American College of Cardiology.
[115] A. Hofman,et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. , 2004, The Journal of nutrition.
[116] M. Schemper,et al. Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis , 2004, Circulation.
[117] M. McKee,et al. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins , 2004, The Journal of cell biology.
[118] R Alagesan,et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). , 2004, American heart journal.
[119] Frank McCormick,et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. , 2004, Genes & development.
[120] S. Hagl,et al. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulate aortic valve calcification , 2004 .
[121] B. Popescu,et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. , 2003, The American journal of cardiology.
[122] M. Enriquez-Sarano,et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. , 2002, Journal of the American College of Cardiology.
[123] M. Budoff,et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium , 2002, The Lancet.
[124] M. Lauer,et al. Effect of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors on the Progression of Calcific Aortic Stenosis , 2001, Circulation.
[125] S. Achenbach,et al. Progression of Aortic Valve Calcification: Association with Coronary Progression of Aortic Valve Calcification Association with Coronary Atherosclerosis and Cardiovascular Risk Factors , 2022 .
[126] A. Gown,et al. Characterization of the Early Lesion of ‘Degenerative’ Valvular Aortic Stenosis: Histological and Immunohistochemical Studies , 1994, Circulation.
[127] K. Watson,et al. Bone morphogenetic protein expression in human atherosclerotic lesions. , 1993, The Journal of clinical investigation.
[128] D. Levy,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.
[129] K. Chandran,et al. Experimental fluid dynamics of aortic stenosis in a model of the human aorta. , 1989, Clinical physics and physiological measurement : an official journal of the Hospital Physicists' Association, Deutsche Gesellschaft fur Medizinische Physik and the European Federation of Organisations for Medical Physics.
[130] R. Miller,et al. Effects of isometric exercise and increased arterial impedance on left ventricular function in severe aortic valvular stenosis. , 1977, British heart journal.
[131] W. Gaasch,et al. Left ventricular compliance: mechanisms and clinical implications. , 1976, The American journal of cardiology.